Device Trial Radar · NCT05920473
Efficacy and Safety Study: Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Movement Disorders in Patients With Intracranial Hemorrhage (ICH).
Last checked: Nov 20, 2026Latest source record: Jun 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
130
Planned (sponsor's estimate)
Start
Jul 1, 2023
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids; Shenzhen Nanshan District Shekou People's Hospital
- First posted
- Jun 27, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study aims to assess the effectiveness and safety of rTMS in the treatment of movement disorders in patients with ICH.
Conditions
- Intracerebral Hemorrhage
Interventions
rTMS with Magstim Rapid 2 magnetic stimulation deviceDevice
The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
sham control with Magstim Rapid 2 magnetic stimulation deviceDevice
In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Fugl-Meyer Assessment (FMA)Time frame: Month 6
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids
Beijing, China · Recruiting
Shenzhen Qianhai Shekou Free Trade Zone Hospital
Shenzhen, China · Recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.